Official UK procurement notice
SUPPLY OF BOTULISM ANTITOXIN HEPTEVALENT (HBAT)
Authority: Ministry of Defence (Central government)
What is being bought
Published requirement descriptionThe Chemical, Biological, Radiological and Nuclear (CBRN) team, part of Defence Equipment and Support (DE&S) organisation within the UK Ministry of Defence (MOD), has placed a contract with Emergent Biosolutions Canada Inc for the supply of Heptavalent Botulism Antitoxin (HBAT) for a period of 3 years. This is necessary to ensure maintenance of the capability with an acceptable stockholding level.
CPV: Immunoglobulins · Purchase
The lotProcurement structure
single lot · no lot value publishedLot #1The Chemical, Biological, Radiological and Nuclear (CBRN) team, part of Defence…
The Chemical, Biological, Radiological and Nuclear (CBRN) team, part of Defence Equipment and Support (DE&S) organisation within the UK Ministry of Defence (MOD), intends to place a contract with Emergent for the supply of Heptavalent Botulism Antitoxin (HBAT) for a period of 10 years (5 + 5 Option Years) with an estimated value of £20M+. This is necessary to ensure maintenance of the capability with an acceptable stockholding level.
Due to the estimated contract value and on the basis that it is to be placed directly with Emergent Biosolutions Canada Inc, the contract will be a Qualifying Defence Contract (QDC) and shall comply with the Single Source Contract Regulations (SSCR) 2014. It is considered that this contract can be awarded using the negotiated procedure without prior publication of a contract notice, pursuant to Public Contracts Regulations 2015; where “Regulation 32 (2)(b)(ii) allows you to use the Negotiated procedure without Prior Publication when the exclusivity is due to technical reasons”.
Summary of the Technical Reason: Emergent Biosolutions Canada Inc are currently the only licensed manufacturer for HBAT (BAT®) which provides antitoxin serotypes A-G for treatment of Botulism worldwide. This product is therefore the only product which provides the full capability to Defence. Additional information: Due to the limitations of the character limit at II 2.4) Description — it is not possible to enter the full details of the single source justification, for full details of the reasoning, please email [email protected] so that it can be forwarded to you.
What it takes to wini
How this buyer will score bids.
The evaluation criteria and weights exactly as published on the notice, grouped by family (price, quality, social value and so on).
Evaluation split and conditions of participation as published; the tender pack may add morei
How this buyer will score bids.
The evaluation criteria and weights exactly as published on the notice, grouped by family (price, quality, social value and so on).
- Lowest price
Procedure terms & legal framework
From the official record- Procedure method
- Negotiated without publication of a contract notice
- Legal basis
- CELEX · 32009L0081 Defence and Security Public Contracts Regulations 2011 (Directive 2009/81/EC)
- Procurement category
- Goods
- Notice status
- Awarded
- Procurement threshold
- Unspecified in notice
- Regulatory regime
- Standard
- Commercial structure
- Stand-alone contract (no framework)
- Competition type
- Competitive procedure
- GPA / WTO covered
- Unspecified in notice
- Recurring procurement
- Unspecified in notice
- First published
- 20 Jun 2022, 16:30 BST
- Last source update
- 3 May 2023, 12:45 BST
- Authority reference
CBRN/00272- FTS notice number
2023/S 000-012644- Classification (CPV)
- Delivery area
- Official registry OCID
ocds-h6vhtk-034881Find a Tender
- Why no open competition
No tenders or no suitable tenders/requests to participate in response to negotiated procedure with prior publication of a contract notice; The works, supplies or services can be provided only by a particular economic operator due to absence of competition for technical reasons
- Published justification
It is considered that this contract can be awarded using the negotiated procedure without prior publication of a contract notice, pursuant to Public Contracts Regulations 2015; where “Regulation 32 (2)(b)(ii) allows you to use the Negotiated procedure without Prior Publication when the exclusivity is due to technical reasons”. Summary of the Technical Reason: Emergent Biosolutions Canada Inc are currently the only licensed manufacturer for HBAT (BAT®) which provides antitoxin serotypes A-G for treatment of Botulism worldwide. This product is therefore the only product which provides the full capability to Defence.
Notice history
1 event · 2 releases on Find a Tender- Buyer details updated3 May 2023, 12:45 BST
Commercial outcome & contract awards
Published awards, contracts and bid statistics, not a forecast| Awarded to | Value | Date | Status |
|---|---|---|---|
| Emergent BioSolutions Canada Inc. | £12,955,456 † | — | Awarded |
| Emergent BioSolutions Canada Inc.Subcontracting: declared | £22,000,000 †same award published again · counted once | — | Awarded |
Contracts
Contract 012644-2023-CBRN/00272-1 · Emergent BioSolutions Canada Inc.
- Signed
- 13 Apr 2023
- Value
- £12,955,456
- Status
- active
SUPPLY OF BOTULISM ANTITOXIN HEPTEVALENT (HBAT) · Emergent BioSolutions Canada Inc.
- Signed
- 7 Jun 2022
- Value
- £22,000,000
- Status
- active
Bid statistics published by the authority
| Bids | SME | VCSE | Valid bid range |
|---|---|---|---|
| 1bids · 1 electronic | — | — | — |
Contracting authority & participating public bodies
Bidders & participating suppliers
2 commercial parties on the notice- Emergent BioSolutions Canada Inc.Awarded supplier
- Emergent Biosolutions Canada IncAwarded supplier
Official documents & specifications
Official links; attachments are not copiedNo document links were published on the notice.